Table 8.
Vaccines administered in the different study groups.
| Study 1: Group 1 [Leiden WVS] | Study 1: Group 2 [Bern WVS] | Study 1: Group 3 [Leiden MVSa] | Study 1: Group 4 [Placebo] | Study 2: Group 1 [Full clinical dose] | Study 2: Group 2 [Intermediate dose] | Study 2: Group 3 [Low dose] | Study 2: Group 4 [Placebo] | |
|---|---|---|---|---|---|---|---|---|
| N = | 94 | 94 | 94 | 47 | 150 | 150 | 150 | 75 |
| Ad26.ZEBOV | ||||||||
| Dose (vp) | 5 × 1010 | 5 × 1010 | 5 × 1010 | — | 5 × 1010 | 2 × 1010 | 8 × 109 | — |
| Batch | #33831 | #33488 | #32642 | — | #33488 | #33488 | #33488 | — |
| MVA-BN-Filo | ||||||||
| Dose (Inf.U) | 1 × 108 | 1 × 108 | 1 × 108 | — | 1 × 108 | 5 × 107 | 5 × 107 | — |
| Batch | #32791 | #32791 | #32791 | #32794 | #32794 | #32794 | — | |
aSame Leiden MVS batch as used in phase 1/2 studies.
Inf.U: infectious units; MVS: master virus seed; vp: viral particles; WVS: working virus seed.